Advertisement
Screener

VERICEL CORPORATION (VCEL) Accumulated Other Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

VERICEL CORPORATION Accumulated Other Comprehensive Income

VERICEL CORPORATION (VCEL) had Accumulated Other Comprehensive Income of -$365.00 thousand as of 2026-06-30, per its 10-Q filed 2026-07-30.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-07-30

  • 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$365.00K.
  • 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$168.00K.
  • 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $275.00K.
  • 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $258.00K.
Period endAccumulated Other Comprehensive Income (Loss), Net of TaxAccumulated Other Comprehensive Income (Loss), Net of Tax as first filed
2026-06-30-$365.00K
10-Q · filed 2026-07-30
2026-03-31-$168.00K
10-Q · filed 2026-05-07
2025-12-31$275.00K
10-Q · filed 2026-07-30
2025-09-30$258.00K
10-Q · filed 2025-11-06
2025-06-30$183.00K
10-Q · filed 2025-07-31
2025-03-31$136.00K
10-Q · filed 2025-05-08
2024-12-31$4.00K
10-K · filed 2026-02-26
2024-09-30$359.00K
10-Q · filed 2024-11-07
2024-06-30-$273.00K
10-Q · filed 2024-08-01
2024-03-31-$245.00K
10-Q · filed 2024-05-08
2023-12-31-$100.00K
10-K · filed 2025-02-27
2023-09-30-$463.00K
10-Q · filed 2023-11-08
2023-06-30-$621.00K
10-Q · filed 2023-08-02
2023-03-31-$636.00K
10-Q · filed 2023-05-10
2022-12-31-$978.00K
10-K · filed 2024-02-29
2022-09-30-$1.15M
10-Q · filed 2022-11-09
2022-06-30-$855.00K
10-Q · filed 2022-08-03
2022-03-31-$613.00K
10-Q · filed 2022-05-04
2021-12-31-$154.00K
10-K · filed 2023-02-23
2021-09-30-$23.00K
10-Q · filed 2021-11-09
2021-06-30-$23.00K
10-Q · filed 2021-08-04
2021-03-31-$47.00K
10-Q · filed 2021-05-05
2020-12-31$14.00K
10-K · filed 2022-02-24
2020-09-30$78.00K
10-Q · filed 2020-11-05
2020-06-30$146.00K
10-Q · filed 2020-08-05
2020-03-31$62.00K
10-Q · filed 2020-05-11
2019-12-31$21.00K
10-K · filed 2021-02-24
2019-09-30$29.00K
10-Q · filed 2019-11-05
2019-06-30$38.00K
10-Q · filed 2019-08-06
2019-03-31$3.00K
10-Q · filed 2019-05-07
2018-12-31-$39.00K
10-K · filed 2020-02-25
2018-09-30-$18.00K
10-Q · filed 2018-11-06
2017-12-31$0.00
10-K · filed 2019-02-26
$397.00K
10-K · filed 2018-03-05
2016-12-31$190.00K
10-K · filed 2018-03-05
2015-12-31$0.00
10-K · filed 2017-03-13
2015-09-30-$71.00K
10-Q · filed 2015-11-13
2015-06-30-$71.00K
10-Q · filed 2015-08-12
2015-03-31-$71.00K
10-Q · filed 2015-05-14
2014-12-31-$71.00K
10-K · filed 2016-03-14
2014-09-30-$70.00K
10-Q · filed 2014-11-13
2014-06-30$5.00K
10-Q · filed 2014-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Greenland Mines Ltd (GRML)United States$2.362B
Immunocore Holdings plc (IMCR)$1.613B-90.43
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80